Viatris Inc.  today announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimod in adults with moderate-to-severe systemic lupus erythematosus (SLE). The ...

Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to dateAdditional safety data and ...

Clinical-stage company Immutep (ASX:IMM) has announced new findings published in Science Immunology that resolve how human ...

The year is ending with a strong flow of clinical results, with Percheron Therapeutics due to release key trial data tomorrow ...

Liver fibrosis is characterized by the excessive accumulation of extracellular matrix components, leading to scarring and impaired liver function. Traditionally linked to viral infections, alcohol ...

Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for ...

Immune checkpoint blockades, or ICBs, have revolutionized treatment for various advanced cancers. However, their effectiveness has plateaued due to therapeutic resistance that renders ...

contribute to the control of lymphocyte activation and death. The initial upregulation of FLIP levels after T-cell activation correlates with the early resistance of activated T cells to Fas ...

Lymphocyte counts help doctors diagnose, stage, and treat chronic lymphocytic leukemia (CLL). Other factors, such as the risk level of the type of CLL you have, also play a role. CLL is a slowly ...

High or low lymphocyte levels can indicate a problem with your immune system. Lymphocytes are a type of white blood cell. They play a key role in your immune system by helping your body fight ...

Favourable safety profile for world's first LAG-3 agonist, IMP761, with no treatment related adverse events to dateAdditional safety data and assessment of PK/PD relationships to follow in first half ...